Fixed combination of oral NEPA (netupitant ‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
ConclusionOral NEPA was highly effective in preventing both acute and delayed CINV over multiple chemotherapy cycles of HEC, AC, and MEC regimens.Clinical trial registration numbersStudy 1, NCT01339260; Study 2, NCT01376297.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Lee Schwartzberg,
Meinolf Karthaus,
Giorgia Rossi,
Giada Rizzi,
Maria E. Borroni,
Hope S. Rugo,
Karin Jordan,
Vincent Hansen Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Dexamethasone | Eyes | Jordan Health | Middle East Health | Oral Cancer | Statistics | Study